| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10013213 | HBV | ENSG00000126218.12 | protein_coding | F10 | No | No | 2159 | P00742 Q5JVE7 Q5JVE8 |
| TVIS10020895 | HBV | ENSG00000126218.12 | protein_coding | F10 | No | No | 2159 | P00742 Q5JVE7 Q5JVE8 |
| TVIS30020164 | HIV | ENSG00000126218.12 | protein_coding | F10 | No | No | 2159 | P00742 Q5JVE7 Q5JVE8 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | F10 |
|---|---|
| DrugBank ID | DB12598 |
| Drug Name | Nafamostat |
| Target ID | BE0000216 |
| UniProt ID | P00742 |
| Regulation Type | inhibitor |
| PubMed IDs | 22251267 |
| Citations | Baek NN, Jang HR, Huh W, Kim YG, Kim DJ, Oh HY, Lee JE: The role of nafamostat mesylate in continuous renal replacement therapy among patients at high risk of bleeding. Ren Fail. 2012;34(3):279-85. doi: 10.3109/0886022X.2011.647293. Epub 2012 Jan 17. |
| Groups | Investigational |
| Direct Classification | Guanidinobenzoic acids and derivatives |
| SMILES | NC(=N)NC1=CC=C(C=C1)C(=O)OC1=CC2=C(C=C1)C=C(C=C2)C(N)=N |
| Pathways | |
| PharmGKB | |
| ChEMBL | CHEMBL273264 |
